3-(3-甲氧基-苯氧基甲基)-哌啶 | 405062-73-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 3-(3-甲氧基-苯氧基甲基)-哌啶
• 英文名称: 3-(3-Methoxy-phenoxymethyl)-piperidine
• 英文别名: 3-[(3-Methoxyphenoxy)methyl]piperidine
• CAS: 405062-73-9
• 化学式: C₁₃H₁₉NO₂
• mdl: MFCD07643220
• 分子量: 221.299
• InChiKey: XUBAZFXZDGWJEM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.538
• 拓扑面积：
  30.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 海关编码：
  2933399090

文献信息

• LIGANDS FOR MONOAMINE RECEPTORS AND TRANSPORTERS, AND METHODS OF USE THEREOF
  申请人：Aquila Brian M.

  公开号：US20090258901A1

  公开（公告）日：2009-10-15

  One aspect of the present invention relates to heterocyclic compounds. A second aspect of the present invention relates to the use of the heterocyclic compounds as ligands for various mammalian cellular receptors, including dopamine, serotonin, or norepinephrine transporters. The compounds of the present invention will find use in the treatment of numerous ailments, conditions and diseases which afflict mammals, including but not limited to addiction, anxiety, depression, sexual dysfunction, hypertension, migraine, Alzheimer's disease, obesity, emesis, psychosis, schizophrenia, Parkinson's disease, inflammatory pain, neuropathic pain, Lesche-Nyhane disease, Wilson's disease, and Tourette's syndrome. An additional aspect of the present invention relates to the synthesis of combinatorial libraries of the heterocyclic compounds, and the screening of those libraries for biological activity, e.g., in assays based on dopamine transporters.

  本发明的一个方面涉及杂环化合物。本发明的第二个方面涉及将杂环化合物用作各种哺乳动物细胞受体的配体，包括多巴胺、血清素或去甲肾上腺素转运体。本发明的化合物将用于治疗许多影响哺乳动物的疾病、状况和疾病，包括但不限于成瘾、焦虑、抑郁、性功能障碍、高血压、偏头痛、阿尔茨海默病、肥胖症、呕吐、精神病、精神分裂症、帕金森病、炎性疼痛、神经痛、Lesche-Nyhane病、威尔逊病和托瑞特综合症。本发明的另一个方面涉及合成杂环化合物的组合库，并对这些库进行生物活性筛选，例如基于多巴胺转运体的测定。
• Rare molecule detection
  申请人：SIEMENS HEALTHCARE DIAGNOSTICS INC.

  公开号：US10809264B2

  公开（公告）日：2020-10-20

  A concentrated sample having enhanced concentration of the one or more different populations of target rare molecules is incubated with, for each different population of target rare molecules, a particulate or non-particulate affinity agent that comprises a specific binding partner that is specific for and binds to a target rare molecule. The affinity agent comprises a mass spectrometry (MS) label precursor or a first alteration agent, which either facilitates the formation of an MS label from the MS label precursor or releases an entity that comprises the MS label precursor from the affinity agent. The MS label corresponds to one of the populations of target rare molecules. A second alteration agent is employed if the first alteration agent does not facilitate the formation of an MS label from the MS label precursor. MS analysis is used to determine each different MS label.

  针对每种不同的目标稀有分子群，将具有一个或多个不同目标稀有分子群的更高浓度的浓缩样品与微粒或非微粒亲和剂进行孵育，亲和剂包括特异性结合伴侣，该特异性结合伴侣对目标稀有分子具有特异性并能与目标稀有分子结合。亲和剂包括质谱（MS）标签前体或第一改变剂，第一改变剂可促进质谱标签前体形成 MS 标签，或从亲和剂中释放出包含 MS 标签前体的实体。MS 标记与目标稀有分子群之一相对应。如果第一种改变剂不能促进 MS 标签前体形成 MS 标签，则使用第二种改变剂。MS 分析用于确定每个不同的 MS 标签。
• RARE MOLECULE DETECTION
  申请人：Siemens Healthcare Diagnostics Inc.

  公开号：EP3149469B1

  公开（公告）日：2020-04-22
• US7294637B2
  申请人：——

  公开号：US7294637B2

  公开（公告）日：2007-11-13
• US7517892B2
  申请人：——

  公开号：US7517892B2

  公开（公告）日：2009-04-14